Marathon Capital Management’s Abiomed Inc ABMD Stock Holding History

Marathon Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-750	Closed	-$269K	–	171
2021 Q4	$269K	Hold	750	–	–	0.06%	144
2021 Q3	$245K	Hold	750	–	–	0.06%	191
2021 Q2	$234K	Sell	750 -30	-4%	-$9.2K	0.05%	173
2021 Q1	$248K	Hold	780	–	–	0.07%	157
2020 Q4	$252K	Buy	780 +5	+0.6%	+$1.38K	0.07%	125
2020 Q3	$214K	Buy	+775	New	+$223K	0.08%	129
2019 Q2	–	Sell	-780	Closed	-$222K	–	118
2019 Q1	$222K	Hold	780	–	–	0.1%	88
2018 Q4	$253K	Buy	780 +30	+4%	+$10.4K	0.13%	79
2018 Q3	$337K	Sell	750 -149	-17%	-$58.7K	0.13%	76
2018 Q2	$367K	Sell	899 -101	-10%	-$36.6K	0.14%	69
2018 Q1	$290K	Buy	+1,000	New	+$253K	0.11%	78

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marathon Capital Management's ABMD Position: Q1 2022 in Review

Marathon Capital Management sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 750 shares — an estimated $269K sold.

Marathon Capital Management first reported a position in ABMD in Q1 2018 and held it in 11 quarters. The position peaked at $367K in Q2 2018. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

Marathon Capital Management reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
Marathon Capital Management sold 750 Abiomed Inc shares in Q1 2022, an estimated $269K.
Marathon Capital Management first reported a position in Abiomed Inc in Q1 2018 and held it in 11 quarters.
Marathon Capital Management's Abiomed Inc position peaked at $367K in Q2 2018.
500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Marathon Capital Management's 13F filing for Q1 2022, filed 13 May 2022.